Antimicrobial

Paratek Pharmaceuticals Announces Inclusion of NUZYRA® (omadacycline) in China’s National Reimbursement Drug List (NRDL)

National Healthcare Security Administration Adds NUZYRA to NRDL for Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin…

2 years ago

US Department of Defense Uniformed Services University Clinical Evaluation of Travelan™ Achieves 150 Recruitment Milestone

Highlights: First participants enrolled in USU Travelan Clinical Trial Field Study157 participants successfully randomized into the Clinical StudyPlans in place…

2 years ago

Qualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic Platform

CARLSBAD, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life…

2 years ago

Kane Biotech Announces First Distribution Agreement for its coactiv+™ Antimicrobial Hydrogel

Salud Pharma to launch product in Colombia, Panama, and Costa RicaWINNIPEG, Manitoba, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Kane Biotech…

2 years ago

T2 Biosystems Announces Extension of Multiyear Innovative Technology Contract with Vizient, Inc.

LEXINGTON, Mass., Dec. 28, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens…

2 years ago

Recce Pharmaceuticals Establishes Anti-Infective Research Unit at Murdoch Children’s Research Institute

Highlights: Recce’s new Anti-Infective Research Unit located within Murdoch Children's world-leading research facilities – internationally recognized for medical research breakthroughsFit-for-purpose…

2 years ago

(Updated) Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation

Los Gatos, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company today announced the…

2 years ago

Daré Bioscience Announces New Development Program, DARE-PDM1, as a Potential First-in-Category Treatment for Primary Dysmenorrhea

DARE-PDM1 Utilizes Proprietary Hydrogel Technology for Vaginal Delivery of Diclofenac, a Nonsteroidal Anti-Inflammatory; Phase 1 Study Targeted for 2023 2022…

2 years ago